NeuroEM Therapeutics

Executive Summary

NeuroEM Therapeutics is a privately held medical device company headquartered in Tampa, Florida, focused on non-invasive neuromodulation for neurodegenerative diseases, particularly Alzheimer's disease. Founded in 2014, the company has developed the MemorEM™ device, which delivers transcranial electromagnetic treatment (TEMT) to the brain. The device has received FDA clearance and demonstrated positive results in a Phase 2 study, showing significant cognitive improvement and stabilization in Alzheimer's patients over a 6-month period. NeuroEM's platform targets the underlying pathology of Alzheimer's by reducing amyloid-beta and tau aggregates, offering a potential disease-modifying approach without the need for drugs. The company is now preparing for commercialization and larger-scale clinical validation. The global Alzheimer's disease market represents a multi-billion-dollar opportunity with high unmet need. NeuroEM's technology differs from pharmacotherapies by providing a non-invasive, home-use device that could complement existing treatments. With a strong safety profile and encouraging efficacy data, the company is positioned to capture a share of the growing cognitive health market. Key upcoming catalysts include the initiation of a pivotal Phase 3 trial, potential FDA clearance for a mild cognitive impairment indication, and strategic partnerships for global distribution. Given the validated technology and clear regulatory pathway, NeuroEM Therapeutics presents an attractive investment opportunity in the neuroscience medical device space.

Upcoming Catalysts (preview)

• Q2 2027Initiation of Phase 3 Pivotal Trial for Alzheimer's Disease65% success
• H1 2027FDA Clearance for Expanded Indication in Mild Cognitive Impairment50% success
• 2026Strategic Partnership or Licensing Agreement for Global Commercialization45% success